EUVIMEDEUVIMED entdecken
Open Access · CC BY-SA 4.0

Pharmacodynamic Relationship Between Infliximab Originator Levels, CDAI Score, and Autoantibodies in Rheumatoid Arthritis

Reem Ghanim Hussein, Mohammed Qasim Al-Atrakji, Ali Hussein Al-Hafidh

Journal Port Science Research · 03.07.2026 · 9 (3) · 541-547

DOI: 10.36371/port.2026.3.6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal Port Science Research, online erschienen am 03.07.2026. Verfasst von Reem Ghanim Hussein und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The inflammatory disorder rheumatoid arthritis (RA) often affects joints. One of the key components of disease is tumor necrosis factor, which is targeted by the monoclonal IgG antibody infliximab. One of the ancestors of infliximab is Remicade. Rheumatoid arthritis (RA) is primarily diagnosed and evaluated using two biomarkers: anti-cyclic citrullinated peptide antibodies (Anti-CCP) and rheumatoid factor (RF).Aim of study: to track the correlation between RF, anti-CCP, and RA disease activity levels and Remicade trough levels. Method: study is a cross-sectional observational study including 48 patients having RA according to ACR/EULAR 2010 criteria and using Remicade for at least 3 months as monotherapy. According to the Clinical Disease Activity Index (CDAI) the participants were divided into four categories accordingly (remission, mild, moderate, and severe). Remicade trough level, anti-CCP, and RF were then assessed for all categories.

Results

Remicade level in the remission group was 5.6±0.1248µg/mL. Each diseased group had a different Remicade trough level: mild (4.22± 0.12µg/mL), moderate (2.342±0.1505), and severe (0.72±0.25). In terms of CDAI scores, the severe group had a total of 20.83+-3.21, the intermediate group had 14.77+-0.62, the mild group had 5.5+-0.6337, and the remission group had 1.34+-0.10. Anti-CCP and RF levels were shown to be negatively correlated with Remicade trough levels.

Conclusions

Remicade blood concentration was shown to be inversely proportional to CDAI score, anti-CCP, and RF improvements.

Zitieren

APA

Hussein, R. G., Al-Atrakji, M. Q., & Al-Hafidh, A. H. (2026). Pharmacodynamic Relationship Between Infliximab Originator Levels, CDAI Score, and Autoantibodies in Rheumatoid Arthritis. Journal Port Science Research, 9(3), 541-547. https://doi.org/10.36371/port.2026.3.6

Vancouver

Hussein RG, Al-Atrakji MQ, Al-Hafidh AH. Pharmacodynamic Relationship Between Infliximab Originator Levels, CDAI Score, and Autoantibodies in Rheumatoid Arthritis. Journal Port Science Research. 2026;9(3):541-547. doi:10.36371/port.2026.3.6

BibTeX
@article{Hussein2026,
  author = {Hussein, Reem Ghanim and Al-Atrakji, Mohammed Qasim and Al-Hafidh, Ali Hussein},
  title = {Pharmacodynamic Relationship Between Infliximab Originator Levels, CDAI Score, and Autoantibodies in Rheumatoid Arthritis},
  journal = {Journal Port Science Research},
  year = {2026},
  volume = {9},
  number = {3},
  pages = {541--547},
  doi = {10.36371/port.2026.3.6}
}
Kostenlos starten →